FDA Approves Differin Epiduo as OTC Acne Treatment

The U.S. Food and Drug Administration has approved Differin Epiduo Acne Gel for over-the-counter sale, Galderma announced on May 22, 2026. The fixed-dose combination pairs adapalene 0.1 percent with benzoyl peroxide 2.5 percent and is cleared for patients aged 12 and older. It is the first retinoid plus benzoyl peroxide combination acne product available in the United States without a prescription.

Galderma said the product will reach Walmart, Ulta, Target, and Amazon shelves in summer 2026. Outside the United States, Epiduo remains prescription-only.

Key Takeaways

• FDA approved adapalene 0.1 percent plus benzoyl peroxide 2.5 percent for OTC use on May 22, 2026, the first fixed-dose retinoid-BPO combination available without a prescription in the U.S.
• Phase 3 data showed up to 70.3 percent reduction in inflammatory acne lesions at Week 12 compared with monotherapy or vehicle gel (Gollnick et al., Br J Dermatol 2009).
• The 2024 American Academy of Dermatology acne guidelines recommend retinoid plus benzoyl peroxide as first-line multimodal therapy, an approach the OTC aisle could not previously deliver in a stable single product.
• Long-term follow-up showed approximately 65 percent total lesion reduction maintained through 12 months of once-daily use (Pariser et al., J Drugs Dermatol 2007).

The Formulation Chemistry That Made an OTC Switch Possible

Combining a retinoid with benzoyl peroxide has been a dermatologic best practice for decades, but the combination has always faced a chemistry problem. Tretinoin, the prototypical prescription retinoid, oxidizes rapidly in the presence of benzoyl peroxide, which is why dermatologists historically instructed patients to apply tretinoin at night and benzoyl peroxide in the morning. The two ingredients did not coexist on the skin or in the tube. Concentration also matters for tolerability, a point covered in our benzoyl peroxide concentration guide.

Adapalene, the retinoid Galderma originally developed and brought to market in 1996, was engineered around that limitation. Unlike tretinoin, adapalene is photostable and chemically resistant to oxidation by benzoyl peroxide, which made a single-tube fixed-dose combination physically possible. The Differin Epiduo formulation is suspended in a proprietary Simulgel base that, according to Galderma, stabilizes and evenly distributes both actives while preserving benzoyl peroxide's antimicrobial potency through the product's shelf life.

The result is a once-daily, one-pump regimen. Adherence research consistently identifies regimen complexity as a primary driver of acne treatment failure, and a stable fixed-dose combination compresses the AM-PM separation that has long complicated retinoid plus BPO protocols.

Why Does This OTC Approval Matter for Acne Care?

The 2024 American Academy of Dermatology acne management guidelines, authored by Reynolds and colleagues and published in the Journal of the American Academy of Dermatology, strongly recommend combining a topical retinoid with benzoyl peroxide as first-line therapy for most patients with acne. Until now, the U.S. OTC aisle could not deliver that recommendation in a single product. Differin (adapalene 0.1 percent monotherapy) became available OTC in 2016, but combining it with benzoyl peroxide required a second purchase and a sequenced routine. This approval consolidates a guideline-aligned protocol into one purchase, removing a barrier for patients who lack ready access to a dermatologist. For patients building a foundation around the new combination, our acne-prone skincare routine guide outlines what to layer alongside it.

Phase 3 trial data submitted to the FDA supported the switch. Gollnick and colleagues reported in the British Journal of Dermatology that the fixed combination outperformed adapalene alone, benzoyl peroxide alone, and vehicle gel across inflammatory lesions, non-inflammatory lesions, and Investigator Global Assessment success rates, with antimicrobial activity beginning on Day 1 and visible lesion reduction by Week 1. A separate 12-month study by Pariser and colleagues in the Journal of Drugs in Dermatology reported approximately 65 percent total lesion reduction sustained through one year of once-daily use, supporting continuous maintenance therapy rather than short-course intervention. When OTC combination therapy is not enough, the cystic acne escalation ladder covers what comes next.

Heather Woolery-Lloyd, MD, a board-certified dermatologist quoted in Galderma's announcement, said the approval "expands access to a clinically proven, dual-active acne solution without the need for a prescription," noting that in clinical practice the combination of broader access and a simple once-daily application supports the consistency that drives outcomes.

When Will Differin Epiduo Appear on Shelves and What Should Buyers Know?

Galderma stated the product will be available at Walmart, Ulta, Target, and Amazon beginning in the summer of 2026. Pricing has not been disclosed. For buyers, two practical considerations follow from the formulation chemistry. Benzoyl peroxide bleaches fabric, so application timing relative to pillowcases, towels, and clothing matters. Adapalene, like all retinoids, increases initial photosensitivity and can cause a retinization period of dryness and mild irritation during the first four to six weeks of use, which the AAD guidelines characterize as expected rather than a reason to discontinue. Daily broad-spectrum sunscreen is non-negotiable with any retinoid-containing regimen.

The approval also reshapes the competitive landscape for OTC acne care. Salicylic acid washes and benzoyl peroxide monotherapy have anchored the drugstore acne aisle for decades. A retinoid-BPO fixed combination at OTC price points and OTC distribution introduces a guideline-grade option into that category for the first time, with implications for both consumer choice and how dermatologists structure escalation conversations with patients who first try over-the-counter options.